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Purpose: The American Society of Anesthesiology (ASA) classification remains the most widely used risk-stratification
system in the world. However, it is not practical in patients undergoing revascularization procedures because most are
classified as ASA III. We hypothesized that ASA III patients can be subdivided into two subgroups, ASA IIIA and ASA
IIIB, simply based on their preoperative functional capacity measured in metabolic equivalents (METS) of <4 or >4,
which would allow the largest group of vascular surgery patients to be appropriately subgrouped for their predicted early
and late postoperative morbidity and mortality.
Methods: All charts of 482 patients (99% men) who underwent revascularization for disabling claudication or critical limb
ischemia between June 2001 and October 2006 were reviewed for demographics, comorbidities, operative and
interventional details, postoperative complications, and outcomes defined as myocardial infarction, stroke, and death.
Preoperative functional capacity information was obtained from the anesthesia records in the electronic charts.
Results: There were 35 patients (7%) in ASA II, 371 patients (77%) in ASA III (45% in ASA IIIA, 32% in ASA IIIB) and
76 patients (16%) in ASA IV. The age, albumin level, prevalence of coronary artery disease, diabetes mellitus,
cerebrovascular disease, renal insufficiency (creatinine >1.5 mg/dL), critical limb ischemia, and length of stay were
significantly higher in ASA IIIB than IIIA patients. Significantly more myocardial infarctions and deaths occurred in IIIB
than in IIIA patients. The overall survival rate was significantly better in ASA IIIA than in ASA IIIB patients. A univariate
Cox proportional model identified coronary artery disease, diabetes mellitus, chronic obstructive pulmonary disease
(COPD), renal insufficiency, hypercholesterolemia, presence of critical limb ischemia, and preoperative albumin level of
<3 g/dL or >3 g/dL as being significantly associated with survival. Multivariate analysis showed being ASA IIIA or IIIB
is an independent predictor of survival, after adjusting for age, coronary artery disease, hyperlipidemia, COPD, and
preoperative albumin levels.
Conclusion: Functional capacity assessment is an integral part of routine preoperative anesthesia evaluation, and we found
this to be very reliable in predicting postoperative morbidity and mortality as well as overall survival in ASA III patients
undergoing peripheral revascularization. This simple modification allows ASA III patients (approximately 80% of
vascular patients) to be unbundled into two very distinct subgroups, which will potentially lead to a more accurate
preoperative risk assessment. ( J Vasc Surg 2008;47:766-73.)The American Society of Anesthesiology’s Physical Sta-
tus Classification (ASA PS) was initially proposed in 1941
by Saklad,1 modified in 1961 by Dripps et al,2 and currently
is the most widely used and standard component of preop-
erative assessment of the physical status of surgical patients.
It is a simple system3,4 based on clinical assessment only,
without the additional need for laboratory and diagnostic
tests or cumbersome mathematic formulas, and is com-
pleted during the routine preoperative anesthesia assess-
ment session. Although this classification has been shown
to be one of the most significant predictors of morbidity
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766and mortality,5-9 we have noticed that nearly all of our
vascular surgery patients are classified as ASA III, making
this system useless for stratification of their perioperative
risks. We also noted that a significant proportion of patients
assigned to ASA III were clearly higher-risk patients than
others in the same category.
A number of various risk-factor assessment systems
have been proposed in an effort to improve the preopera-
tive risk assessment of surgical patients,10-12 but none have
been adopted to replace the simple, widely used ASA PS
classification. We observed a significant variation in func-
tional capacity in ASA III patients and decided to reclassify
all ASA III patients into IIIA or IIIB, according to their
ability to perform  4 metabolic exercise equivalents
(METS) or 4 METS, as described in the Duke Activity
Status Index and the American Heart Association (AHA)
exercise index.13-15 We hypothesized that in our vascular
surgery patients undergoing leg revascularizations for dis-
abling claudication (DC) or critical limb ischemia (CLI),
patients classified as ASA IIIA and IIIB would have differ-
ent perioperative morbidity and mortality risks and that
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cantly different.
METHODS
Study design. Between June 1, 2001, and October
31, 2006, the 482 patients (99% men) who presented to
the Veterans Administration (VA) Western New York
Healthcare System with DC or CLI (Rutherford categories
3 to 6)16 and who underwent at least one endovascular,
open, or hybrid intervention were entered into a prospec-
tively maintained computerized database. Patients who un-
derwent primary amputations were excluded. Patients were
subclassified as ASA IIIA and ASA IIIB by a retrospective
review of the preanesthesia evaluation and by exercise tol-
erance of 4 METS or 4 METS. Clinical characteristics
and outcomes were compared between groups. The study
protocol was reviewed and approved by the Institutional
Review Board at Buffalo VA Medical Center.
Methodology. The patients’ demographic character-
istics, comorbidities, ASA class, clinical characteristics, pre-
operative albumin level, functional status, preoperative ar-
terial studies, procedures performed, type of anesthesia
used (local, epidural/spinal, general), perioperative mor-
bidity and mortality, length of stay (LOS), follow-up arte-
rial studies, and status of their limbs and general health
were recorded.
A member of the anesthesia department saw all patients
before any intervention scheduled in the operating room.
In addition to the routine preanesthetic evaluation includ-
ing a history and physical examination, this clinic coordi-
nates with the primary care services to medically optimize
surgical patients for their procedures. Patients’ ASA class
was determined during this visit, as was previously de-
fined.3,4
As a part of this routine evaluation, the patient’s exer-
cise tolerance was graded and documented as either 4
METS or 4 METS, as described by the Duke Activity
Status Index15 and the AHA exercise index.13,14 Patients
who could walk one flight of stairs independently were
considered to have an exercise tolerance of4 METS. The
initial history, physical examination, and electrocardio-
gram (ECG) assessment focused on the identification of
potentially serious cardiac disorders, including prior
myocardial infarction (MI) and angina pectoris, heart
failure, symptomatic arrhythmias, or presence of an im-
plantable defibrillator. A stepwise strategy following the
AHA/American College of Cardiology (ACC) guide-
lines was used to determine the need for further cardiac
testing in high-risk patients by the presence or absence of
major clinical predictors (eg, unstable angina, decom-
pensated heart failure or severe valvular disease), func-
tional capacity, and surgery-specific risk. Indications for
further cardiac testing and treatments were the same as
those in the nonoperative setting, but their timing was
dependent on the urgency of the intervention and the
patient’s risk factors. Cardiac testing ranged from non-
invasive stress testing to echocardiography to preopera-
tive coronary angiography.Patients who met the requirements for perioperative
-blockade were administered metoprolol, which was ti-
trated to the desired effect before the surgical procedure
and was continued intraoperatively and postoperatively.
Invasive intraoperative monitoring was reserved for those
with a recent MI complicated by heart failure, those with
significant coronary artery disease (CAD), and those with
systolic or diastolic left ventricular dysfunction, cardiomy-
opathy, or valvular disease, or a combination of these, who
were undergoing prolonged open procedures. Pulmonary
artery pressure monitoring using Swan-Ganz catheteriza-
tion was not used in any of the patients in this study;
however, continuous pressure monitoring with an indwell-
ing arterial catheter was used in most patients undergoing
open procedures. Patients were not started on statin drugs
if preoperative statins had not already been started by their
primary physician.
All open bypass, endovascular, and hybrid procedures
using the OEC 9800 system (GE Medical Systems, Salt
Lake City, Utah) were performed by board-certified vascu-
lar surgeons in the operating room. The vascular surgery
service is the only provider for all endovascular interven-
tions in our hospital. All patients were followed up in the
vascular laboratory postoperatively, at 3 and 6 months, and
every 6 months thereafter for clinical assessment, ankle-
brachial index measurements, duplex ultrasound imaging,
and angiography when clinically indicated. Owing to a
computerized charting system in the VA, the information
on the time to demise was available for all patients in our
series.
Patients. There were 35 patients (7%) in ASA II, 371
patients (77%) in ASA III, and 76 patients (16%) in ASA IV.
The mean age of ASA III patients was 68.5  10.4 years.
All but four patients were males (98.9%). Of the ASA III
patients, 45% were ASA IIIA and 32% were ASA IIIB.
Demographics and comorbidities of these patients are re-
Table I. Demographics and morbidities in American
Society of Anesthesiology IIIA and IIIB patients
Variable ASA IIIA ASA IIIB P
Total, No. (%) 218 (45) 153 (32)
Age, mean  SD years 65.6  9.7 72.6  10.1 .001
Albumin, mean  SD g/dL 3.6  0.5 3.2  0.6 .001
Creatinine, mean  SD 1.22  0.39 1.28  0.42 .2
CAD, % 52 67 .004
Hypertension, % 75 74 .84
Diabetes mellitus, % 43 61 .0004
CVD, % 14 23 .03
Hyperlipidemia, % 72 60 .014
COPD, % 20 25 .27
Renal insufficiency, % 16 26 .01
Dialysis, % 1 7 .005
Albumin 3 g/dL, % 15 38 .0001
Critical limb ischemia, % 55 96 .0001
ASA, American Society of Anesthesiology; CAD, coronary artery disease;
CLI, critical limb ischemia; COPD, chronic obstructive pulmonary disease;
CVD, cerebrovascular disease.ported in Table I.
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the intervention in 21% of the ASA IIIA group and in 10%
of the ASA IIIB group (P  .02), and 6 months before
the intervention in 21% and 25% of patients, respectively.
Coronary angiography was performed 6 months of the
intervention in 5% of ASA IIIA patients, in 1% of ASA IIIB
patients, and 6 months before the intervention in 15% in
each group (P .33). Preoperative coronary revasculariza-
tion was performed in two patients (1%) in ASA IIIA and
one patient (1%) in ASA IIIB. None was performed in
preparation for the vascular surgery procedure. Coronary
revascularization had been performed 6 months before
the intervention in 21% of ASA IIIA and 16% of ASA IIIB
patients (P  .27).
The types of revascularizations performed in each
group are summarized in Table II. The distribution of the
levels of interventions was similar between the ASA IIIA
and IIIB patients in those who had open bypass or hybrid
procedures; however, more infrainguinal procedures were
performed in the ASA IIIB group than in the IIIA group in
those who underwent endovascular interventions (P 
.001).
Definitions. ASA class III is defined as a patient with
severe systemic disease. This is between ASA II, a patient
with mild systemic disease, and ASA IV, a patient with
severe systemic disease that is a constant threat to life.3,4
Coronary artery disease was defined as documented an-
gina pectoris, MI, congestive heart failure, or a history of
coronary artery revascularization. Renal insufficiency was
defined as a serum creatinine level 1.5 mg/dL. Cere-
brovascular disease (CVD) was defined as a history of
stroke, transient ischemic attack, carotid artery revascu-
Table II. The open, hybrid, and endovascular
interventions performed in American Society of
Anesthesiology IIIA and IIIB patients
Intervention
ASA IIIA
(n  218)
No. (%)
ASA IIIB
(n  153),
No. (%)
Endovasculara
Aortoiliac 48 (47) 10 (13)
Femoropopliteal 45 (44) 45 (60)
Infrapopliteal 10 (9) 20 (27)
P .001
Open
Aortobifemoral bypass 8 (9) 2 (3)
Extra-anatomic bypass 8 (9) 7 (12)
Infrainguinal bypass 70 (78) 48 (83)
FEA only 4 (4) 1 (2)
P .74
Hybrid
Iliac stent plus FEA 12 (48) 8 (40)
Iliac stent plus EAB 3 (12) 4 (20)
Iliac stent plus IIB 10 (40) 8 (40)
P .83
ASA, American Society of Anesthesiology; EAB, extra-anatomic bypass;
FEA, femoral endarterectomy; IIB, infrainguinal bypass.
aThe most distal level of endovascular intervention.larization, or a known 50% carotid artery stenosis.Hypertension was defined as a previous documentation
of systolic blood pressure of 150 mm Hg, or diastolic
blood pressure of 90 mm Hg, and taking at least one
medication for blood pressure control. Hypercholester-
olemia was defined as fasting cholesterol level 200
mg/dL, a low-density lipoprotein level130 mg/dL, or
triglycerides level 200 mg/dL. Diabetes mellitus was
defined as fasting plasma glucose level110 mg/dL or a
hemoglobin A1c level 7%. Hybrid procedures were
defined as an open procedure (endarterectomy, bypass)
combined with an endovascular intervention for improv-
ing inflow or runoff performed at the time of the open
procedure.
Perioperative morbidities were defined as those that were
recorded 30 days after the index procedure. Postoperative
MI was diagnosed by ECG changes, with or without angina,
confirmed by elevations of serum troponin-I and creatinine
kinase-MB (CK-MB) levels. Routine troponin-I or CK-MB
testing in the absence of any clinical suspicion was not
performed. A cerebrovascular accident (CVA) was defined
as any cerebral event including transient ischemic attacks
and strokes. Perioperative deaths were those occurring30
days of the index procedure.
Statistical analysis. Patients’ demographic character-
istics were reported using descriptive statistics. Clinical
characteristics and risk factors were compared using the
Fisher exact test or 2 test for categoric variables, and by
t test for continuous variables. The associations between
proposed subclassifications and postoperative complica-
tions were evaluated with logistic regression analysis, and
the odds ratios (OR) and the corresponding 95% confi-
dence intervals (CI) were estimated. Univariate Cox pro-
portional hazard modeling17 was used to identify potential
factors associated with survival. The candidate variables
included CAD, diabetes mellitus (DM), chronic obstruc-
tive pulmonary disease (COPD), CVD, renal insufficiency,
hyperlipidemia, indication for intervention, and preopera-
tive albumin level. All the significant variables selected from
the univariate Cox model were included in a stepwise
multivariate Cox proportional model to evaluate their in-
dependent prognostic effects. Hazard ratios and 95% con-
fidence limits were estimated from this model. Kaplan-
Meier analysis18 was used to compare overall survival, and
the log-rank test was used for comparison between groups.
All P values are two-sided with  level 0.05. Data analysis
was performed using SAS 9.1 software (SAS Institute Inc,
Cary, NC).
RESULTS
The mean age and albumin levels were significantly
different between ASA IIIA and IIIB patients, whereas
creatinine levels were not (Table I). More patients in the
ASA IIIB group had DM, CAD, CVD, and renal insuffi-
ciency, and were more likely to have an albumin level 3
g/dL and present with CLI. The ASA IIIA patients were
more likely to have hyperlipidemia. The use of -blockers
(ASA IIIA vs IIIB, 55% vs 57%), angiotensin converting-
enzyme inhibitors (ACEI, 54% vs 49%), enteric-coated
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similar between groups. More patients were taking statins
(58% vs 46%, P  .02) in the ASA IIIA group, and more
patients were receiving warfarin in the ASA IIIB group
(23% vs 34%, P  .03).
The LOS was significantly less in ASA IIIA (4.4  5.7
days) than IIIB patients (8.3  11.6 days, P  .001). The
IIIB patients had significantly more complications,MI, and
death than IIIA patients (Table III). The type of procedure
performed did not affect the 30-day outcomes for endovas-
cular vs open vs hybrid for MI (1.1% vs 2.7% vs 4.4%, P 
.34), stroke (0% vs 0.6% vs 0%, P  .48), or death (2.2% vs
2.7% vs 6.6%, P  .37).
The overall survival was significantly different between
ASA IIIA and IIIB groups (P  .001; Fig, Table IV). The
type of intervention (endovascular vs open vs hybrid) had
no effect on survival, and was similar within the ASA IIIA
and IIIB groups (data not shown). The overall survival in
ASA IIIA patients was significantly better than in ASA IIIB
patients even when only those with CLI were compared
(48-month overall survival, 72%  6% vs 41%  5%; P 
.001).
Univariate Cox proportional model identified CAD,
DM, COPD, CVD, renal insufficiency, hyperlipidemia,
Table III. The association between American Society of
Anesthesiology IIIA and IIIB groups and postoperative
(30-day) complications
Event
ASA
IIIA, %
ASA
IIIB, % OR (95% CI) P
Any complication 12.5 21.5 1.95 (1.11-3.4) .02
MI 0.5 4.6 10.4 (1.27-85.41) .03
Stroke 0 0.7 . . . .96
Death 0.5a 5.9 13.56 (1.70-108.20) .01
ASA, American Society of Anesthesiology; CI, confidence interval; MI,
myocardial infarction; OR, odds ratio.
aCommitted suicide.
Fig. Overall survival in ASA IIIA and ASA IIIB groups.the indication for intervention, and albumin level at 3g/dL or3 g/dL as significantly associated with survival
(Table V). Multivariate analysis showed that being classi-
fied ASA IIIA or IIIB was an independent predictor of
survival after adjusting other factors including age, CAD,
hyperlipidemia, COPD, and preoperative albumin level3
g/dL or 3 g/dL (Table VI).
The statin drug use in the 123 patients without hyper-
lipidemia was 5.7% and was associated with improved over-
all survival at 4 years of 74% 4% vs 53% 5% (relative risk
[RR], 2.18; 95% CI, 1.47-3.22; P  .0001). This was also
true for both ASA IIIA (87% 4% vs 67% 7%; P .005)
and ASA IIIB patients (49% 8% vs 39% 6%; P .047).
However, when only patients with hyperlipidemia were
included, the survival benefit from statin usage did not
persist (RR, 1.62; 95% CI, 0.90-2.90; P  .11). In con-
trast, no survival difference was associated with the use of
-blockers, ACEIs, enteric-coated aspirin, clopidogrel, or
Table IV. Overall survival in groups
Survival, mean  SD, %
Group 12-mo 24-mo 36-mo
ASA IIIA 95  2 91  2 86  3
ASA III 84  2 78  2 71  3
ASA IIIB 67  4 59  4 50  5
ASA, American Society of Anesthesiology.
Table V. Univariate Cox proportional model showing
the maximum likelihood estimates for survival
Variable HR 95% CL P
CAD 0.48 0.32, 0.73 .0006
Hypertension 0.94 0.61, 1.44 .77
Diabetes mellitus 0.55 0.37, 0.81 .003
CVD 0.60 0.39, 0.93 .02
Hyperlipidemia 1.91 1.31, 2.78 .0008
COPD 0.56 0.37, 0.85 .006
Renal insufficiency 0.58 0.38, 0.89 .01
CLI 3.82 2.10, 6.97 .0001
Albumin 3 g/dL 3.03 2.07, 4.45 .0001
CAD, coronary artery disease; CLI, critical limb ischemia; CL, confidence
limits;COPD, chronic obstructive pulmonary disease;CVD, cerebrovascular
disease; HR, hazard ratio.
Table VI. Multivariate analysis for predicting survival in
American Society of Anesthesiology III patients
Variable HR 95% CL P
Age 1.03 1.01, 1.06 .005
CAD 0.56 0.36, 0.87 .01
Hyperlipidemia 1.57 1.07, 2.31 .02
COPD 0.55 0.36, 0.83 .005
ASA subgroup 3.34 2.17, 5.14 .0001
Albumin 3g/dL 2.61 1.76, 3.86 .0001
ASA, American Society of Anesthesiology; CAD, coronary artery disease;
CL, confidence limits; COPD, chronic obstructive pulmonary disease; HR,
hazard ratio.warfarin in these patients.
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Among the many preoperative risk stratification strate-
gies,5,6,7-12 the most commonly used continues to be the
ASA classification.5-9 This classification system has been
criticized for being too simple, too subjective, and associ-
ated with wide variability,19-22 but it remains a strong
predictor of postoperative morbidity andmortality.5-8,23,24
Although other methods have been proposed for replacing
the ASA classification,10-12,22 none of these have suc-
ceeded, likely because they are too complex or are not
applicable without performing additional tests. Currently,
few data are available on the use of the ASA classification
system to predict postoperative morbidity and mortality in
vascular surgery patients. Patients in ASA III and IV are
usually grouped into one high-risk category, and because
most vascular patients have a systemic disease process, 75%
to 80% are classified as ASA III,24 making this system
impractical in this patient population.
Most of our patients (77%) undergoing revasculariza-
tion procedures for DC or CLI were classified as ASA III.
Reclassifying them according to their functional capacity
(4METS or4METS) enabled dividing this group into
two subgroups consisting of 45% (ASA IIIA) and 32% (ASA
IIIB) of all patients. The patients in ASA IIIB were older by
an average of 7 years than ASA IIIA patients and were more
likely to have CAD, DM, CVD, renal insufficiency, a lower
albumin level, and CLI. Their postprocedural LOS was
longer, and they weremore likely to experienceMI or die in
the early postoperative period, which was not influenced by
the type of intervention performed. The overall survival was
influenced by CAD, DM, COPD, CVD, renal insuffi-
ciency, hyperlipidemia, indication for intervention, and
albumin level of 3 g/dL or 3 g/dL; however, being in
the ASA IIIA or IIIB group was found to independently
influence overall survival by multivariate analysis. This sim-
ple subgrouping was very effective in differentiating the
subgroups in patients harboring a severe systemic disease;
that is, ASA III class patients.
The association of older age with increased periopera-
tive and long-term mortality is not surprising. It was one of
the major factors influencing ASA level determination in a
recent report on using National Surgical Quality Improve-
ment Program (NSQIP) risk factors to validate ASA PS
classification levels.6 We found this to be a significant factor
influencing the subclassification of ASA III, but not neces-
sarily a determinant of functional capacity by itself. Al-
though ASA IIIB patients had more comorbidities, a sig-
nificant percentage of ASA IIIA patients also had significant
comorbidities (52% had CAD, 43% had DM, 20% had
COPD, 14% had CVD, 16% had renal insufficiency), and
overall survival was found to be independently determined
by our functional capacity-based subclassification. Because
none of the comorbidities could be identified as exclusively
contributing to ASA IIIA vs IIIB subclassification, we
conclude that it is more the patient’s functional capacity,
rather than the particular comorbidities, that determine the
early and late outcomes in these patients.We found serum albumin levels to independently affect
mortality rates, which was also a significant predictor in the
NSQIP database.5,6 Although this is a significant predictor,
its incorporation into the ASA subclassification is impracti-
cal, mainly because this information is not readily available
in the preoperative anesthesia evaluation and is not rou-
tinely obtained in most hospitals.
The use of statin drugs and -blockers to reduce periop-
erative and long-term cardiovascular morbidity and mortality
has been increasingly reported in recent years.25-27 We also
found that patients taking statin drugs had better survival
within each group. Because most of the factors affecting
survival—age, comorbidities, presentation mode—are not
easily modifiable in our ASA IIIB patients, increased use of
statin drugs may improve outcomes in this high-risk group
of patients. The 53% rate of statin drug use in our patients
was very similar to the 56% reported by Coronary Artery
Revascularization Prophylaxis (CARP) Trial investiga-
tors,28,29 who also suggested that a more aggressive use
of this class of drugs could potentially improve survival in
these patients. We would like to point out, however, that
ASA IIIA patients survived better than the IIIB patients,
whether or not they were taking statin drugs.
Our results confirmed the previous reports30,31 that the
presence of CLI was an independent predictor of poor
survival as well as a predictor of being assigned to the ASA
IIIB group. More patients with CLI were in the ASA IIIB
group than in the ASA IIIA group in our series; however,
55% of patients in ASA IIIA group had CLI yet maintained
a better functional capacity than other patients in ASA IIIB
with CLI and had significantly better survival. Functional
capacity is difficult to assess in patients with DC or CLI
owing to the nature of their disease process; however, we
think that a patient who cannot achieve the level of activity
we chose (4 METS or 4 METS) probably belongs to a
higher-risk group, irrespective of the cause of the functional
limitations.
We chose 4 METS as the line of separation between
ASA IIIA and IIIB patients. This is the functional capacity
level at which the need for further cardiac testing before
surgery is determined in patients with intermediate clinical
predictors of heart disease or in those with minor clinical
predictors who are scheduled for high-risk surgical proce-
dures, as suggested by Eagle et al in the ACA/AHA guide-
lines.13,14 Therefore, this assessment was available in the
preoperative anesthesia notes in our patients. An interesting
finding was that a smaller proportion of patients with
poorer functional capacity (ASA IIIB) underwent noninva-
sive (10% vs 26%) and invasive testing (1% vs 5%) than did
the ASA IIIA patients 6 months of the revascularization.
This likely is due to the presence of limb-threatening isch-
emia in most of the patients in the ASA IIIB group, making
the proposed procedure more urgent than in those present-
ing with claudication.
In addition, preoperative cardiac testing was not neces-
sary in nearly all of the patients undergoing endovascular
interventions. The procedure is considered low risk, so
patients proceeded directly with revascularization, espe-
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cularization even in a selected group of patients in the CARP
Trial with DC and CLI has been reported not to lower early
and late mortality rates after extremity revascularization pro-
cedures,28 we do not think that a more aggressive coronary
revascularization would have made any difference in our pa-
tients. Incidentally, the type of intervention—endovascular,
hybrid, or open—had no impact on survival.
The overall 30-day mortality rate of 2.7% in our pa-
tients was almost identical to 2.6% rate reported by CARP
investigators in their analysis of patients who underwent leg
revascularization28; however, most of these occurred in
ASA IIIB group in our series. The 30-day mortality rate of
5.9% in our ASA IIIB group seem excessive, but because
this subgroup was never analyzed separately, it is impossible
to comment on this figure at this time.
The NSQIP database, which was started in 1994,5,6
remains one of the most well maintained databases for
preoperative risk assessment and recently expanded to the
private sector. The ASA classification was found to be one
of the strongest predictors of morbidity and mortality in a
large group of surgery patients, a large percentage of which
included vascular patients.5,6 Davenport et al6 recently
proposed that the NSQIP risk factors were a more reliable
means to validate ASA PS classification and challenged the
statement in the ASAWeb site4 that no additional informa-
tion (other than the annual edition of ASA Relative Value
Guide) is available that will help further define the ASA
categories. The authors identified age, current smoking,
history of hypertension, morbid obesity, preoperative
coma, dyspnea, preoperative impaired sensorium, low he-
matocrit, and previous cardiac operation as NSQIP risk
factors that most influenced ASA PS levels, but only a few of
these are applicable to vascular surgery patients.
An important disadvantage of theNSQIP is that its data
entry is a labor-intensive procedure, requires highly skilled
personnel, and involves entering 60 preoperative risk fac-
tors, 18 intraoperative factors, and 22 postoperative com-
plications. In addition, none of the data obtained are avail-
able during the preoperative anesthesia evaluation, and
therefore cannot be used as a preoperative risk assessment
tool, whereas the patient’s ASA class is determined at the
end of the 15- to 20-minute interview by the anesthesia
practitioner. We think that the only reasonable practical
way to further define the ASA categories is by simply
incorporating functional capacity to the ASA III class.
Attempts to incorporate multiple risk factors, such as those
suggested by Davenport et al,6 are not likely to gain wide
acceptance due to their complexity and inapplicability,
especially in vascular surgery patients.
The weaknesses of our study include its retrospective
nature and that is a single-center study with relatively small
numbers. Nearly all the patients were men, and only pa-
tients who underwent leg revascularization were included.
The patients were not routinely ruled out for an MI after
the interventions; however, this practice differs little from
that of most centers treating this group of patients. Allobservations were made by the vascular surgery team, with
no independent observer assessments in any patients.
CONCLUSION
Although the ASA classification has its weaknesses and
inconsistencies, it remains one of the most powerful preop-
erative assessment tools used in clinical practice. It was
shown to be the single strongest predictor of morbidity and
mortality for combined general and vascular surgery pa-
tients in the yet unpublished American College of Surgeons
NSQIP report.6 Therefore, optimizing its use bymodifying
its biggest subgroup, ASA III, into IIIA and IIIB by
using a simple clinical evaluation of a widely used system
(4 METS or 4 METS) seems to be reasonable to
improve the use of this widely used classification. This
simple, inexpensive, and widely applied classification may
be very helpful in developing a more accurate risk strat-
ification in vascular patients as we approach the era of
pay-for-performance.32
We found that incorporating functional capacity into
the preoperative risk assessment divides the ASA III pa-
tients into two very distinct subgroups (IIIA and IIIB).
Patients in IIIB are significantly older, have lower preoper-
ative serum albumin levels, and are more likely to have
CAD, DM, renal insufficiency (creatinine level 1.5 mg/
dL), dialysis-dependence, a serum albumin level3 g/dL,
and CLI. Their LOS was also significantly longer. The rates
for 30-dayMI, death, and overall survival were significantly
different between ASA IIIA and IIIB patients, as were the
overall survival rates. These findings were independent of
the type of interventions. This simple modification allows
ASA III patients, who comprise 80% of vascular patients, to
be unbundled into two very distinct subgroups, which will
potentially lead to a more appropriate preoperative risk
assessment. Larger-scale studies in different patient groups
are needed to confirm these results before the change is
adopted for all patients undergoing surgical procedures.
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Dr James Black (Baltimore, Md). I wished to thank the society
for the privilege of discussing this paper. I congratulate DrDosluoglu
on this important contribution and, of course, applaud his diligence in
providing me with a copy of the manuscript well in advance.
The evaluation of preoperative risk before noncardiac surgery
and interventions aimed towards reducing that risk has an integral
part of the modern practice of all vascular and endovascular sur-
geons. This week, a simple PubMed search of coronary risks and
vascular surgery yielded no less than 7,000 hits. As such, this paper
represents a novel departure from the previous studies that contin-
ually reduced preoperative risks to an unwieldy series of biomark-
ers, clinical markers, noninvasive, and invasive testing with the
sundry scoring systems to lay out the risk assessment in some
digestible way.
Dr Dosluoglu and his colleagues retrospectively reviewed 482tion and critical limb ischemia, insightfully, dividing the major
portion of their patients based upon functional status and examin-
ing their outcomes. To further inform the audience, 4 METS is
equivalent to 4 miles per hour of walking and, given our popula-
tion and claudicators, a simple estimate would be 4 MET equiva-
lent activity would be taking out the trash or gardening in their
backyard, according to the CDC [Centers for Disease Control].
The authors foundmany statistical differences between these 2
groups; in a multivariate analysis, coronary artery disease, diabetes,
renal insufficiency, COPD, and critical limb ischemia were ex-
tremely predictive of postoperative mortality in poor outcomes. Of
all the variables, critical limb ischemia clearly resounded through
your paper and carries an odds ratio of 14.7 with pretty tight
confidence intervals to predict one’s patients landing as a IIIB
patient before their operation. So I have three questions regarding
this finding. Firstly, would it be justifiable in your estimation to
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 4 Dosluoglu et al 773consider any critical limb ischemia patients, as highest risk regard-
less of them lacking other significant comorbidities? Secondly, the
AHA and the American College of Cardiology recognized PAD
[peripheral arterial disease] as cardiac risk-equivalent disease, and
should critical limb ischemia really be the emphasis of that deter-
mination and not just a simple wastebasket diagnosis of PAD? And
lastly, going back to my introduction and the lack of proven
efficacy of any preoperative testing strategy to yield survival benefit,
have any of your IIIBs, to your knowledge, undergone cardiac
catheterization to determine the presence of three-vessel disease or
left main disease; the situation wherein many still believe our
mantra of perioperative beta blockade may not be enough to pull
these patients through a vascular reconstruction? Thanks again for
the privilege of discussing your work.
Dr Hasan H. Dosluoglu: Thanks for the insightful ques-
tions. You are correct in the sense that the critical limb ischemia
was seen in 92% in the IIIB group and less than that in the IIIA
group. However, when we looked only the critical limb ischemia
patients, they still turned out to have different outcomes in IIIA
and IIIB patients. So, obviously this does make a difference in this
subgroup that the critical limb ischemia turned out to be one of the
most significant predictors, but these subclassifications are really
not meant for just critical limb ischemia patients, and we would like
to extent it to other subgroups. We do have critical limb ischemia
patients, say diabetic patients with some ulcer, who by definitionHowever, some of them do have very good functional status with
good outcomes. So, it is a very good predictor in this subgroup.
You are correct, but I think we still like to keep the functional status
as the major determinant of IIIA and IIIB.
The second question: We did perioperative cardiac evaluation
as routine pre-op, but we did not specifically look for coronary
angiograms or cardiac tests for the purposes of the study. Does the
VA population have perioperative -blockade? All the risk adjust-
ment is actually emphasized heavily in the VA, and this is pretty
much a very uniformly treated group of patients. We are taking
these METS subclassification from the cardiologists in a way
because this is really in the Eagle’s noncardiac surgery risk assess-
ment, so it is not surprising that the coronary artery disease is the
most significant determinant of the IIIA and IIIB in that way. So it
is vice versa, I guess, the cardiac and peripheral limbs affecting each
other in a way.
Dr Martin Back (Tampa, Fla): Nice presentation and good
data. I am not aware of actually any validation data for functional
status that has been proposed in the ACC/AHA classifications for
risk stratification part of noncardiac surgery, so this is good data. I
am gonna echo what Dr Black mentioned, that I think you need to
separate out that ASA IIIG group and take out the critical limb
ischemia patients and look specifically at whether or not condition-
ing or deconditioning affects this functional status and has a
prognostic effect in these patients.are classified as having critical limb ischemia because of tissue loss. Dr Dosluoglu. Thank you.
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